

Cyanidin-3-glucoside enhances mitochondrial function and biogenesis in a human hepatocyte cell line.

著者（英）	ABDULMAJID HASAN MOGALLI RASHAD
year	2019
その他のタイトル	Cyanidin-3-glucoside のヒト肝細胞におけるミトコンドリア機能亢進作用の解析
学位授与大学	筑波大学 (University of Tsukuba)
学位授与年度	2018
報告番号	12102甲第9206号
URL	http://doi.org/10.15068/00156493

筑 波 大 学

博 士 （ 医 学 ） 学 位 論 文

Cyanidin-3-glucoside enhances mitochondrial function
and biogenesis in a human hepatocyte cell line.

(Cyanidin - 3-glucoside のヒト肝細胞におけるミトコンドリア機能
亢進作用の解析)

2018

筑波大学大学院博士課程人間総合科学研究科

氏 名 RASHAD ABDULMAJID HASAN MOGALLI

TABLE OF CONTENTS

	Page
TITLE PAGE-----	1
TABLE OF CONTENTS-----	2
LIST OF ABBREVIATIONS-----	3
ABSTRACT-----	4
INTRODUCTION-----	6
MATERIAL AND METHODS-----	13
RESULTS-----	19
DISCUSSION-----	32
CONCLUSION -----	37
LIMITATIONS -----	38
ACKNOWLEDGMENT-----	39
REFERENCES--	40
CITATION-----	51

LIST OF ABBREVIATIONS

Cy3g: Cyanidin-3-glucoside

PGC-1 α : Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha

SIRT1: Sirtuin 1

MMP: Mitochondrial membrane potential

ATP: Adenosine triphosphate

TFAM: Mitochondrial transcription factor A

NRF1: Nuclear respiratory factor-1

ROS : reactive oxygen species

CPT-1 β : Carnitine palmitoyltransferase 1 beta

CDE: choline-deficient, ethionine-supplemented diet

PFK-1: Phosphofructokinase 1

ABSTRACT

Mitochondrial dysfunction has been identified as one of the primary factors contributing to liver diseases. Pathways that control mitochondrial biogenesis are potential therapeutic targets for the amelioration of hepatocyte dysfunction and liver disease. Research on natural pharmacological agents that ameliorate liver diseases has intensified over the last two decades. Cyanidin-3-glucoside (Cy3g), a dietary flavonoid compound extracted from a wide variety of fruits and vegetables, reportedly has several beneficial health effects. In this study, we used an adult human hepatoma cell line (HuH7) to investigate the effects of the Cy3g polyphenolic compound on mitochondrial function and biogenesis in vitro. An increase in intracellular mitochondrial reductase levels was observed after treatment with Cy3g, but cytotoxicity was not induced. In addition, mitochondrial membrane potential and ATP production were increased following Cy3g treatment. Cy3g treatment also resulted in a dose- and time-dependent upregulation of the gene expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α), a transcription factor considered a master regulator of mitochondrial biogenesis and metabolism.

Additionally, the expression of sirtuin 1 (SIRT1), which plays a key role in deacetylating PGC-1 α , was also increased in a dose- and time-dependent manner. Cy3g treatment also increased the expression of downstream PGC-1 α genes, nuclear respiratory factor 1 and mitochondrial transcription factor A (TFAM). Our results suggest that Cy3g has potential as a hepatoprotective therapeutic agent that enhances mitochondrial function and biogenesis in hepatocytes.

INTRODUCTION

- Mitochondria role in health and diseases

Mitochondria are the main organelles that maintain energy production, control metabolism and regulate stress within cells (Wallace 2005; Nunnari and Suomalainen 2012). Mitochondrial health is an important parameter of overall cell health. Mitochondrial dysfunction has been found to be a key factor leading to the development of a variety of diseases, such as neurodegenerative disorders (Johri and Beal 2012), endocrine dysfunction (Chow et al. 2016), and several metabolic disorders, such as insulin resistance (Petersen et al. 2003; Morino et al. 2006), as well as hepatic and cardiovascular diseases (Gustafsson and Gottlieb 2007; Nassir and Ibdah 2014).

- Mitochondrial dysfunction and liver diseases

Many studies have reported the direct relationship between mitochondrial dysfunction and liver diseases (Pessayre et al. 2002; Begriche et al. 2006; Rector et al. 2010; Nassir and Ibdah 2014).

Disrupted hepatocyte metabolism results in lipid retention in hepatocytes(Fig.1). This retention has been attributed to failed long chain fatty acid catabolism via hepatic mitochondrial β -oxidation (Fabbrini et al. 2010).




Fig.1 Mitochondrial role in liver disease; hepatic mitochondrial dysfunction leads to elevated oxidative stress and eventual progression of liver disease.

- PGC-1 α as a master of mitochondrial biogenesis

In Homo sapiens and eukaryotic animals, cell mitochondrial biogenesis and metabolic control are orchestrated by several factors. Among these, one important factor has emerged in the past decade, called Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α). PGC-1 α controls mitochondrial biogenesis via the activation of several downstream genes, such as mitochondrial transcription factor A (TFAM), which is triggered by nuclear respiratory factor-1/-2 (NRF1/2) (Finck and Kelly 2006). Fasting or hypothermia, which help the cell adapt to nutritional status, can trigger PGC-1 α . Disruption of this mechanism has been associated with the development of mitochondrial dysfunction-related diseases (Vega et al. 2000; Scarpulla 2011). Sirtuin 1 (SIRT1), a homolog of SIRT2, was observed to cooperate with PGC-1 α to regulate hepatocyte gluconeogenesis and glycolysis-related genetic controlling processes (Rodgers et al. 2005). A study reported that PGC-1 α impairment in the CDE fed rodent liver

results in impaired mitochondrial biogenesis and lipid metabolism, eventually exacerbating fatty liver diseases (Aharoni-Simon et al. 2011)(Fig.2).




Fig.2 PGC-1α in mitochondria; Impairment of the master of mitochondrial biogenesis PGC-1α leads to less mitochondrial biogenesis, gluconeogenesis and β-oxidation of free fatty acids in liver.

- Therapeutic potential of Anthocyanins

The search has intensified for natural product treatments that can replace or synergize with current pharmaceutical products and minimize pharmaceutical side effects and financial burdens (Bagchi et al. 2015). Anthocyanidins, which are anthocyanins bound with aglycone are a group of flavonoids. Anthocyanins are pigments that exist in many fruits and vegetables and result in red, blue and violet colours. Recently, anthocyanins have gained attention for their protective and health benefits. Anthocyanins bioavailability was investigated in human and animals, using extracts as anthocyanin sources , anthocyanins were rapidly absorbed in both animal models (Fornasaro et al.2016; Kalt et al., 2008; Ali et al., 2005; de Boer et al.,2005) and humans (Bub et al., 2001; Cao & Prior, 1999; Matsumoto et al., 2001; Mazza et al.,2002; Prior & Wu, 2006). Cyanidin-3-glucoside (Cy3g), a water-soluble anthocyanin dietary flavonoid compound extracted from a wide variety of fruits and vegetables, has been reported to

have multiple beneficial effects(Fig.3). A clinical study found that the intake of this compound minimizes cardiovascular risk (Cassidy et al. 2013).




Fig.3 The chemical structure for Cyanidin-3-glucoside

- Mitochondria as a potential target of Anthocyanin

Cy3g resulted in increased brown adipose tissue mitochondrial function (You et al. 2017). In addition, treating different rodents models with Cy3g resulted in hepatocyte protection and prevented obesity and insulin resistance (Jiang et al. 2014, Wei et al. 2011). Our previous reports indicate that Cy3g benefits skeletal muscle

aerobic capacity and enhances adipose tissue metabolism (Matsukawa et al. 2015, 2017).

The HuH7 cell line is a well-differentiated, established adult hepatoma cell line that provides a good in vitro system to test the effects of natural compounds on hepatocyte metabolism (Chavez-Tapia et al. 2012; Krelle et al. 2013). In this study, we investigated the effects of Cy3g on mitochondrial function and biogenesis using the HuH7 cell line as a hepatocyte model.

MATERIALS AND METHODS

- Chemicals

Cy3g (98% HPLC Purity) was purchased from Tokiwa Phytochemical Co., Ltd. Japan. The well-differentiated human hepatocellular carcinoma HuH7 cell line was purchased from the National Institutes of Biomedical Innovation Health and Nutrition JCRB Bank (JCRB No. JCRB0403, Tokyo, Japan). The cell culture medium was Dulbecco's modified Eagle's medium (DMEM) containing low glucose (Sigma, Tokyo, Japan). Penicillin/streptomycin and trypsin/EDTA were obtained from Lonza (Tokyo, Japan). Fetal bovine serum (FBS) and Hanks' balanced salt solution (HBSS) were purchased from Gibco (USA). Sodium dodecyl sulfate (SDS) was purchased from Wako (Tokyo, Japan). 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and Triton X-100 were purchased from Sigma (MO, USA). MTT was purchased from Dojindo Co., Ltd. (Kumamoto, Japan). Guava ViaCount and Check Kit reagents were purchased

from Guava Technologies Co., Ltd. USA. Rhodamine 123 was purchased from Wako.

- Cell culture

Cells were cultured in 75-cm² culture flasks with low glucose DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin (5000 µg/ml)–streptomycin (5000 IU/ml) at 37 °C in an incubator with 5% CO₂. The growth medium was changed every other day, and the experiments were completed with cells between passages 3–7 and at no more than 70–80% confluence. Passaging was performed with trypsin/EDTA.

- MTT assay

Cells were seeded at a concentration of 3×10^3 cells per well in DMEM 10% FBS culture medium in 96-well plates and cultured for 24 h. Then, the cells were treated with different concentrations of Cy3g compound for different time intervals. Under dark settings, the cells were then washed with phosphate-buffered

saline (PBS) and incubated with MTT reagent (5 g/l) for 3 h. MTT formazan crystals were then dissolved in 10% SDS and kept overnight at room temperature. Optical density was measured using a Powerscan HT plate reader (Dainippon Sumitomo Pharma Co., Ltd., Japan). The results were normalized to those of the control group. All experiments were performed in triplicate.

- Guava cell count

The Guava ViaCount assay , which is a DNA-binding fluorescence dye, was conducted on untreated and treated suspension cultures according to the manufacturer's protocol (Cat. No. 4000-0040). Guava ViaCount staining reagent (380 µl) was added and mixed with 20 µL of cell suspension in a 1.5-mL tube. Then, the suspension was kept in the dark for 5 min at room temperature. A Guava PCA machine (Guava Technologies) was used to analyze the samples. Readings were acquired using Cytosoft software (version 2.1.2). Machine performance was assessed using the

Guava check application with a Guava Check kit (Cat. No. 4500-0020).

- ATP assay

Cellno ATP assay reagent (Toyo Inc., Tokyo, Japan) was used in accordance with the manufacturer's protocol to measure intracellular ATP levels. HuH7 cells were treated with different concentrations of Cy3g compound for various times and then incubated with ATP assay reagents for 15 min at room temperature. A Powerscan HT plate reader (Dainippon Sumitomo Pharma Co., Ltd.) was used to detect luminescence.

-Mitochondrial membrane potential (MMP)

MMP was measured using rhodamine 123 fluorescent dye. Cells were treated with Cy3g at various concentrations and time intervals. Then, the cells were incubated with the rhodamine 123 dye (10 µg/ml) in 10 mM HEPES-HBSS buffer (pH 7.4) for 20 min at 37 °C. After lysing HuH7 cells using 1% Triton X-100

(Sigma-Aldrich™ Co., Ltd., USA), a Powerscan HT plate reader (Dainippon Sumitomo Pharma Co., Ltd., Japan) was used to quantify rhodamine 123 fluorescence intensity (excitation 485 nm/emission 528 nm).

- Real-time PCR analysis

HuH7 cells were plated in a 60-mm cell culture dish. After 24 h, the cells were incubated with different Cy3g concentrations for different times (1, 3, 6, and 24 h). Total RNA from HuH7 cells was isolated using Macherey–Nagel’s RNA extraction kit (Macherey–Nagel GmbH & Co. KG, Germany). The extraction process was executed according to the manufacturer’s protocol. The quantity of RNA was evaluated using a NanoDrop 2000 Spectrophotometer (Thermo Scientific™, Inc., Wilmington, DE, USA). Reverse transcription (RT) reactions were carried out with the SuperScript III RT kit (Invitrogen Co., Ltd., Carlsbad, CA, USA). The following primer sets and TaqMan probes for experimental genes were purchased from Applied Biosystems

(CA, USA): GADPH (Hs02786624_g1), PGC-1 α (Hs01016719_m1), TFAM (Hs00273327_s1), NRF1 (Hs00602161_m1), SIRT1 (Hs01009006_m1), CPT-1 β (Hs03046298_s1) and PFK1 (Hs01075411_m1). The mRNA expression level of each gene was normalized using GADPH as an internal control. Fold changes were calculated using $2^{-\Delta\Delta C_t}$.

- Statistical analysis

All experiments were repeated three times. The experimental data are presented as the mean \pm standard deviation. When two values were compared (control vs. treatment), statistical significance was assessed by Student's unpaired *t*-test using Microsoft Excel (iOS Version 2011; Microsoft Inc., USA). $P \leq 0.05$ was considered statistically significant.

RESULTS

- Cy3g increased mitochondrial reduction activity

The MTT (3-(4,5-dimethylthiazol-2-yl)-diphenyl tetrazolium bromide) assay was used to examine the mitochondrial reduction of the Cy3g compound on the HuH7 hepatoma cell line at different times and concentrations. The study revealed that Cy3g did not reduce cell viability. The MTT assay is a classic method for evaluating cell mitochondrial function via intracellular mitochondrial reduction of MTT to formazan (Brand and Nicholls 2011). Compared with the control, the increased absorbance induced by 25 and 50 μ M Cy3g indicated that cell mitochondrial reduction activity was upregulated dose-dependently by 130 and 139%, respectively, at 24 h. In addition, absorbance was increased to 112 and 125% after treatment with 25 and 50 μ M Cy3g, respectively, at 48 h (Fig. 4). Guava cell assay was used to assess cell proliferation, treatment with Cy3g did not decrease or increase cell proliferation (Fig. 5).




Fig. 4 Effect of Cy3g treatment on cell proliferation; Cell proliferation was measured using MTT assays, and the HuH7 adult human hepatoma cell line was cultured at 3×10^3 cell per well with or without (control) different concentrations of Cy3g (1, 5, 10, 25 or 50 μM) for different time periods (24 or 48 hr). Values represent the means of three independent experiments \pm standard deviation. The bars with asterisk marks are significantly different from the control at $P \leq 0.05$ (*) or $P \leq 0.01$ (**)




Fig. 5 Cytotoxicity of Cy3g; Guava count assays were used to detect the number of adult human hepatoma HuH7 cells cultured with or without (control) 50 μM Cy3g for 24 hr. Values represent the means of three independent experiments \pm standard deviation. The bar with NS mark is non significantly different from the control.

- Cy3g increased intracellular ATP production in HuH7 cells

The compound had no cytotoxic effect on HuH7 cells (MTT assay result). Then, Cellno ATP assay was used to determine the effects of Cy3g on the intracellular ATP levels in HuH7 cells. Luminescence readings indicated that compared with the control treatment, Cy3g treatment significantly increased the intracellular ATP level to 109% at the 25 μ M concentration and to 117% at the 50 μ M concentration (Fig. 6).




Fig. 6 Effect of Cy3g treatment on ATP production; measurement of intracellular ATP in the HuH7 adult human hepatoma cell line, cultured without Cy3g (control) or with different concentrations of Cy3g (5, 25 or 50 µM) for different time periods (24 or 48 hr). Values represent the means of three independent experiments \pm standard deviation. The bars with asterisk marks are significantly different from the control at $P \leq 0.05$ (*) or $P \leq 0.01$ (**).

- Cy3g increased the MMP

The majority of ATP production occurs within the mitochondria via oxidative phosphorylation: the mitochondrial electron transport chain creates an electrochemical gradient that induces ATP synthesis and generates the MMP, which is a good indicator of mitochondrial health (Sakamuru et al. 2016). Rhodamine 123 is a cationic, membrane-permeable fluorescent staining dye that is used to measure the inner MMP, which is a sensitive indicator of mitochondrial health (Sakamuru et al. 2016). In our experiment, compared with those of control-treated cells after 24 h, fluorescence readings significantly increased to 108 and 117% in 25 and 50 μ M Cy3g-treated cells, respectively. After 48 h of treatment, fluorescence was increased 112% in cells treated with 50 μ M Cy3g (Fig. 7), indicating that Cy3g increased the mitochondrial transmembrane potential in HuH7 cells.




Fig. 7 Effect of Cy3g treatment on mitochondrial MMP; measurement of mitochondrial depolarization activity in the HuH7 adult human hepatoma cell line, cultured without Cy3g (control) or with different concentrations of Cy3g (5, 25 or 50 µM) for different time periods (24 or 48 hr). Values represent the means of three independent experiments \pm standard deviation. The bars with asterisk marks are significantly different from the control at $P \leq 0.05$ (*) or $P \leq 0.01$ (**).

- Cy3g treatment dose- and time-dependently increased PGC-1 α and SIRT1 gene expression levels

The polyphenol Cy3g dose-dependently upregulated PGC-1 α and SIRT1 gene expression, and these genes have been reported to play a key role in the control of metabolic adaption and mitochondrial biogenesis (Finck and Kelly 2006; Ventura-Clapier et al. 2008; Cantó and Auwerx 2009). Cy3g significantly upregulated PGC-1 α gene expression in a dose-dependent manner, from a 1.5-fold change at the 25 μ M dose to a twofold change at the 50 μ M dose ($*P \leq 0.01$) (Fig. 8a). Regarding SIRT1 gene expression, 25 and 50 μ M Cy3g increased the level 1.2- to 1.7-fold, respectively (Fig. 8b).




Fig. 8 PGC-1 α and SIRT1 upregulation by cy3g treatment; the effects of Cy3g on HuH7 cell PGC-1 α (Fig. 8a) and SIRT1 (Fig. 8b) mRNA expression after treatment with different concentrations of Cy3g (25 μ M and 50 μ M) for 24 hrs. The gene expression level was normalized to the GAPDH expression level. Values are expressed as the means \pm standard deviation of triplicate experiments. * $P \leq 0.05$ and ** $P \leq 0.01$ indicate that the mean value is significantly different from that of the control group.

Cy3g resulted in a time-dependent increase in PGC-1 α and SIRT1 gene expression levels. The 25 μ M concentration was selected to evaluate PGC-1 α and SIRT1 levels at different time intervals (1, 3, 6, and 24 h). PGC-1 α and SIRT1 gene expression levels peaked at 3 h in treated cells compared with those in control cells, with significant 2.0-fold increases (* $P \leq 0.01$). Cy3g treatment also significantly increased PGC-1 α and SIRT1 gene expressions after 24 hrs. , with fold changes of 1.50 and 1.27, respectively ($P \leq 0.01$) (Fig. 9).




Fig. 9 Cy3g effect on PGC-1α and SIRT1 mRNA expression with time; effects of Cy3g on HuH7 cell PGC-1α and SIRT1 mRNA expression levels were measured at different time intervals (1, 3, 6 and 24 h after treatment with 25 μM Cy3g), and the gene expression level was normalized to the GADPH expression level. Values are expressed as the mean ± standard deviation of triplicate experiments. * $P \leq 0.05$ and ** $P \leq 0.01$ indicate that the mean value is significantly different from that of the control group.

- The effect of Cy3g on PGC-1 α and SIRT1 downstream genes

Treatment with Cy3g (25 μ M) for 24 hrs significantly increased the expression of PGC-1 α -coactivated downstream genes, such as NRF1, approximately 2.5-fold. Cy3g increased the TFAM level by approximately 1.3-fold. TFAM is a nuclear-encoded transcription factor that plays a key role in mitochondrial DNA replication and transcription and is regulated by NRF1 (Finck and Kelly 2006). In addition, Cy3g increased CPT-1 β levels approximately 2.3-fold (Fig. 10). CPT-1 β is located within the mitochondrial outer membrane and is considered the rate-limiting enzyme of mitochondrial β -oxidation, as it controls mitochondrial uptake of long chain acyl-CoA fatty acids. Increased PGC-1 α levels have been found to increase the CPT-1 β level, thus increasing the fatty acid oxidative capacity of the mitochondria (Song et al. 2010; Nikolić et al. 2012). Furthermore, Cy3g treatment increased phosphofructokinase 1 (PFK-1) gene expression approximately 1.7-fold. PFK-1 is an important regulator of glycolysis (Han et al. 2016) (Fig. 10).




Fig. 10 The effects of Cy3g treatment on PGC-1 α downstream gene mRNA expression in HuH7 cells; The effects of Cy3g on HuH7 cell PGC-1 α downstream gene mRNA expression levels were measured at 24 hr. After treatment with 25 μ M Cy3g, the gene expression levels (TFAM, NRF1, CPT-1 β , PFK-1) were normalized to the GADPH expression level. Values are expressed as the means \pm standard deviation of triplicate experiments. * $P \leq 0.05$, ** $P \leq 0.01$ indicates that the mean value is significantly different from that of the control group.

DISCUSSION

The search for natural herbal compounds and extracts that treat or prevent disease has intensified during the last decade. Several studies have reported the beneficial effects of a variety of natural compounds, such as resveratrol, quercetin and catechin on health (Watson et al. 2013).

Among anthocyanin compounds, Cy3g, a phenol pigment that belongs to the flavonoid family, has been shown to have beneficial effects in several in vitro and in vivo clinical trials (Watson et al. 2013). Clinical trials had found that Cy3g's bioavailability is higher than previously perceived, and their metabolites are detected in the blood within 48 h after oral intake (Czank et al. 2013). Previously, we reported that Cy3g enhances skeletal muscle mitochondrial biogenesis by upregulating PGC-1 α levels via the elevation of cyclic AMP levels (Matsukawa et al. 2017). PGC-1 α is reportedly an essential factor for upregulating hepatic metabolism and is key for overall liver metabolism (Leone et

al. 2005; Finck and Kelly 2006). This study examined the effects of Cy3g on mitochondrial function and biogenesis in hepatic cells (HuH7) and elucidated the underlying mechanism. In this study, we found that Cy3g induced PGC-1 α activity. This induction of PGC-1 α gene expression was associated with a similar tendency for increased SIRT1 gene expression.

Increased expression of PGC-1 α -coactivated downstream genes, such as nuclear respiratory factor-1 (NRF1), which encodes respiratory chain subunits and other proteins necessary for mitochondrial function, was observed (Finck and Kelly 2006). Moreover, Cy3g increased the gene expression of mitochondrial transcription factor A (TFAM), a nuclear-encoded transcription factor that plays a key role in mitochondrial DNA replication and transcription and is regulated by NRF1 (Finck and Kelly 2006). Cy3g also increased CPT-1 β gene expression, which is located within the mitochondrial outer membrane and is considered the rate-limiting enzyme of mitochondrial β -oxidation as CPT-1 β

controls the mitochondrial uptake of long chain acyl-CoA fatty acids. Moreover, increased PGC-1 α levels have been found to increase the CPT-1 β level, thus increasing the fatty acid oxidative capacity of mitochondria (Song et al. 2010; Nikolić et al. 2012). Cy3g also increased PFK-1 gene expression, an important regulator of glycolysis (Han et al. 2016). Currently, lifestyle modification and caloric restriction are the only treatments for nonalcoholic fatty liver diseases (Nassir and Ibdah 2016). Some polyphenol compounds, such as resveratrol, have shown calorie restriction-mimicking effects in mammalian diseases and can ameliorate liver fat accumulation in high-fat diet mouse models, mostly due to the activation of metabolism-sensing signaling systems (Baur et al. 2006; Ajmo et al. 2008; Li et al. 2016). While several pathways control mitochondrial function, biogenesis and free fatty acid oxidation, a recently identified member of the Peroxisome proliferator-activated receptor gamma (PPAR- γ) coactivator family, PGC-1 α , serves as a major regulator of the nuclear receptors that control metabolic pathways and is

expressed in tissues with high oxidative capacity such as muscle and liver tissues (Finck and Kelly 2006). Hepatocytes extracted from PGC-1 α -deficient mice exhibit reduced mitochondrial respiration rates, indicating a reduced hepatic fatty acid oxidation capacity (Leone et al. 2005). SIRT1 coexists with the transcription factor PGC-1 α and plays an important role in PGC-1 α activation via deacetylation (Rodgers et al. 2005). SIRT1 and PGC-1 α signaling is important in the protection of in vitro hepatocyte models against mitochondrial oxidative stress (Tan et al. 2015). Furthermore, pharmacological activation of SIRT1 by polyphenol in HepG2 protected against FAS induction and lipid accumulation (Hou et al. 2008).

Several studies have revealed the crucial role of sirtuins generally and SIRT1 specifically in liver diseases (Nassir and Ibdah 2016; Ding et al. 2017). SIRT1, an NAD⁺-dependent protein deacetylase, is an important regulator of energy homeostasis, enhanced mitochondrial metabolism, antioxidative protection,

lipid catabolism and glucose homeostasis (Canto and Auwerx 2012). Both in vitro and in vivo models of SIRT1 deficiency have shown a tendency for increased lipid accumulation in the liver and down regulation of de novo hepatic lipid synthesis transcription factors, such as sterol regulatory element binding protein-1c (SREBP-1c) and carbohydrate response element binding protein (ChREBP) (Purushotham et al. 2009; Wang et al. 2010). Previously, Guo et al. (2012) reported that Cy3g decreased lipid accumulation in hepatocytes. Jiang et al. (2014) demonstrated the beneficial effect of Cy3g in protecting primary mouse hepatocytes from hyperglycemia-induced mitochondrial depolarization, and preincubation with Cy3g improved cell survival and reduced reactive oxygen species (ROS) generation by modulating mitochondrial dysfunction. Pathways that control mitochondrial biogenesis have been studied extensively to identify future therapeutic approaches to treat the mitochondrial dysfunction that leads to various liver and metabolic diseases (Davinelli et al. 2013).

CONCLUSION

Our experiments showed that in a human-derived hepatocyte model (HuH7 cells), Cy3g is a potent activator of the SIRT1 and PGC-1 α signaling pathways, inducing mitochondrial biogenesis and function and triggering an increase in PGC-1 α downstream genes, and these effects are dose- and time-dependent (Fig.11). Therefore, this compound should be considered a therapeutic or preventive approach for diseases caused by hepatic cell mitochondrial dysfunction.




Fig. 11 Graphical abstract

Limitations

In regard to the limitations of this study; we understand that primary cultured hepatocyte might be the suitable cell line for the study of drug metabolism studies. However the access to the primary hepatocytes is restricted, those cells usually show phenotypic instability and functional variation making their utility for routine testing complicated (Castell et al. 2006). Several liver-derived hepatocytes cell lines such as HuH7 or HepG2 have been developed for drug metabolism studies or drug toxicity screening. These hepatoma cell lines provide an accessible source, stable phenotype and longer lifespan. However, the majority of currently used hepatoma cell lines might not be as good as primary cultured hepatocytes, given that hepatoma cells contain a low level of drug-metabolising enzymes (Donato et al. 2013). For future studies of food or drug metabolism studies we suggest the use of new approaches with more metabolic competent cell lines such as immortalised hepatocytes or progenitor-induced hepatocytes.

ACKNOWLEDGMENTS

I want to thank professor Nobuhiro Ohkohchi for his supervision and support during the PhD course, for being my wide gate to future academia. Along with professor Hiroko Isoda whose patience and support was the cornerstone of this research work.

Professor Oda Tatsuya's support was essential to overcome the hardships, his research and personal charisma had taught me a lot.

Dr.Shimomura and Dr.Matuskawa, without them this work could never be done. Dr.Shimomura believed in me and encouraged me through, facilitating the road of the PhD.

Dr.Matsukawa taught me a lot during this process, his guidance, knowledge and patience are forever appreciated.

To My lovely wife, Tomomi Yanase who believed me. And for all of those supported me .

This research was supported by the Center of Innovation Program funded by the Ministry of Education Culture and Sports (MEXT), Japan, and Japan Science and Technology (JST).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

REFERENCES

Aharoni-Simon M, Hann-Obercyger M, Pen S, Madar Z, Tirosh O (2011) Fatty liver is associated with impaired activity of PPAR γ -coactivator 1 α (PGC1 α) and mitochondrial biogenesis in mice. *Lab Invest* 91:1018–1028.

Ajmo JM, Liang X, Rogers CQ, Pennock B, You M (2008) Resveratrol alleviates alcoholic fatty liver in mice. *Am J Physiol Gastrointest Liver Physiol* 295:G833–G842.

Bagchi D, Preuss HG, Swaroop A (2015) Nutraceuticals and functional foods in human health and disease prevention. CRC Press, Boca Raton, FL

Baur JA, Pearson KJ, Price NL et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 444:337–342.

Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. *Mitochondrion* 6:1–28.

Brand MD, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. *Biochem J* 435:297–312.

Bub A, Watzl B, Heeb D, et al (2001) Malvidin-3-glucoside bioavailability in humans after ingestion of red wine, dealcoholized red wine and red grape juice. *European Journal of Nutrition* 40:113–120. doi: 10.1007/s003940170011

Canto C, Auwerx J (2012) Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? *Pharmacol Rev* 64:166–187.

Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB (2013) High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women: clinical perspective. *Circulation* 127:188–196.

Cao, G., & Prior, R. L. (1999). Anthocyanins are detected in human plasma after oral administration of an elderberry extract. *Clin Chem*, 45(4), 574-576.

Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechn MJ (2006) Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. *Expert Opinion on Drug Metabolism & Toxicology* 2:183–212. doi: 10.1517/17425255.2.2.183.

Chavez-Tapia NC, Rosso N, Tiribelli C (2012) Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. *BMC Gastroenterol* 12:20.

Chow J, Rahman J, Achermann JC, Dattani MT, Rahman S (2016) Mitochondrial disease and endocrine dysfunction. *Nat Rev Endocrinol* 13:92–104.

Czank C, Cassidy A, Zhang Q, et al (2013) Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a ¹³C-tracer study. *The American Journal of Clinical Nutrition* 97:995–1003. doi: 10.3945/ajcn.112.049247

Davinelli S, Sapere N, Visentin M, Zella D, Scapagnini G (2013) Enhancement of mitochondrial biogenesis with polyphenols: combined effects of resveratrol and equol in human endothelial cells. *Immun Ageing* 10:28.

de Boer, V. C., Dihal, A. A., van der Woude, H., Arts, I. C., Wolfram, S., Alink, G.M., Rietjens, I. M., Keijer, J., & Hollman, P. C. (2005). Tissue distribution of quercetin in rats and pigs. *JNutr*, 135(7), 1718-1725.

Ding R-B, Bao J, Deng C-X (2017) Emerging roles of SIRT1 in fatty liver diseases. *Int J Biol Sci* 13:852–867.

Donato M, Jover R, Gómez-Lechón M (2013) Hepatic Cell Lines for Drug Hepatotoxicity Testing: Limitations and Strategies to Upgrade their Metabolic Competence by Gene Engineering. *Current Drug Metabolism* 14:946–968. doi: 10.2174/1389200211314090002.

Kalt, W., Blumberg, J. B., McDonald, J. E., Vinqvist-Tymchuk, M. R., Fillmore, S. A., Graf, B. A., O'Leary, J. M., & Milbury, P. E. (2008). Identification of anthocyanins in the liver, eye, and brain of blueberry-fed pigs. *J Agric Food Chem*, 56(3), 705-712

Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* 51:679–689.

Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. *J Clin Invest* 116:615–622.

Guo H, Liu G, Zhong R, Wang Y, Wang D, Xia M (2012) Cyanidin-3-O- β -glucoside regulates fatty acid metabolism via an AMP-activated protein kinase-dependent signaling pathway in human HepG2 cells. *Lipids Health Dis* 11:10.

Gustafsson AB, Gottlieb RA (2007) Heart mitochondria: gates of life and death. *Cardiovasc Res* 77:334–343

Han H-S, Kang G, Kim JS, Choi BH, Koo S-H (2016) Regulation of glucose metabolism from a liver-centric perspective. *Exp Mol Med* 48:e218.

Hou X, Xu S, Maitland-Toolan KA (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated Protein Kinase. *J Biol Chem* 283:20015–20026.

Fornasaro S, Ziberna L, Gasperotti M, et al (2016) Determination of cyanidin 3-glucoside in rat brain, liver and kidneys by UPLC/MS-MS and its application to a short-term pharmacokinetic study. *Scientific Reports*. doi: 10.1038/srep22815

Jiang X, Tang X, Zhang P, Liu G, Guo H (2014) Cyanidin-3-O- β -glucoside protects primary mouse hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction and the PI3K/Akt pathway. *Biochem Pharmacol* 90:135–144.

Johri A, Beal MF (2012) Mitochondrial dysfunction in neurodegenerative diseases. *J Pharmacol Exp Ther* 342:619–630.

Krelle AC, Okoli AS, Mendz GL (2013) Huh-7 human liver cancer cells: a model system to understand hepatocellular carcinoma and therapy. *J Cancer Ther* 04:606–631.

Leone TC, Lehman JJ, Finck BN et al (2005) PGC-1 α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. *PLoS Biol* 3:e101.

Li X, Wang H, Gao Y, Li L, Tang C, Wen G, Yang Y, Zhuang Z, Zhou M, Mao L, Fan Y (2016) Quercetin induces mitochondrial biogenesis in experimental traumatic brain injury via the PGC-1 α signaling pathway. *Am J Transl Res* 8:3558–3566

Matsukawa T, Inaguma T, Han J, Villareal MO, Isoda H (2015) Cyanidin-3-glucoside derived from black soybeans ameliorate type 2 diabetes through the induction of differentiation of preadipocytes into smaller and insulin-sensitive adipocytes. *J Nutr Biochem* 26:860–867.

Matsukawa T, Motojima H, Sato Y, Takahashi S, Villareal MO,

Isoda H (2017) Upregulation of skeletal muscle PGC-1 α through the elevation of cyclic AMP levels by Cyanidin-3-glucoside enhances exercise performance. *Sci Rep* 7:44799.

Matsumoto, H., Inaba, H., Kishi, M., Tominaga, S., Hirayama, M., & Tsuda, T. (2001). Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms. *J. Agric. Food Chem.*, 49(3), 1546-1551.

Mazza G, Kay CD, Cottrell T, Holub BJ (2002) Absorption of Anthocyanins from Blueberries and Serum Antioxidant Status in Human Subjects. *Journal of Agricultural and Food Chemistry* 50:7731–7737.

Mazza G, Brouillard R (1987) Recent developments in the stabilization of anthocyanins in food products. *Food Chemistry* 25:207–225. doi:10.1016/0308-8146(87)90147-6

Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. *Diabetes* 55:S9–S15.

Nassir F, Ibdah J (2014) Role of mitochondria in nonalcoholic fatty liver disease. *Int J Mol Sci* 15:8713–8742.

Nassir F, Ibdah JA (2016) Sirtuins and nonalcoholic fatty liver disease. *World J Gastroenterol* 22:10084–10092.

Nikolić N, Rhedin M, Rustan AC, Storlien L, Thoresen GH, Strömstedt M (2012) Overexpression of PGC-1 α increases fatty acid oxidative capacity of human skeletal muscle cells. *Biochem Res Int* 2012:714074

Nunnari J, Suomalainen A (2012) Mitochondria: in sickness and in health. *Cell* 148:1145–1159.

Pessayre D, Mansouri A, Fromenty B (2002) V. Mitochondrial dysfunction in steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* 282:G193–G199.

Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 300:1140–1142.

Prior, R. L., & Wu, X. (2006). Anthocyanins: structural characteristics that result in unique metabolic patterns and biological activities. *Free Radic Res*, 40(10),1014-1028.

Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. *Cell Metabol* 9:327–338.

Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, Ibdah JA (2010) Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. *J Hepatol* 52:727–736.

Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1 α and SIRT1. *Nature* 434:113–118.

Sakamuru S, Attene-Ramos MS, Xia M (2016) Mitochondrial membrane potential assay. *Methods Mol Biol* 1473:17–22.

Scarpulla RC (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochim Biophys Acta* 1813:1269–1278.

Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, Hori RT, Cook GA, Park EA (2010) Peroxisome proliferator activated receptor α (PPAR α) and PPAR gamma coactivator (PGC-1 α) induce carnitine palmitoyltransferase 1A (CPT-1A) via independent gene elements. *Mol Cell Endocrinol* 325:54–63.

Tan M, Tang C, Zhang Y (2015) SIRT1/PGC-1 α signaling protects hepatocytes against mitochondrial oxidative stress induced by bile acids. *Free Radical Res* 49:935–945.

Vega RB, Huss JM, Kelly DP (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. *Mol Cell Biol* 20:1868–1876.

Ventura-Clapier R, Garnier A, Veksler V (2008) Transcriptional control of mitochondrial biogenesis: the central role of PGC-1 α . *Cardiovasc Res* 79:208–217.

Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu Rev Genet* 39:359–407.

Wang RH, Li C, Deng CX (2010) Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. *Int J Biol Sci* 6:682–690.

Watson RR, Preedy VR, Zibadi S (2013) Polyphenols in human health and disease. Elsevier Science, LondonGoogle Scholar

Wei X, Wang D, Yang Y et al (2011) Cyanidin-3-O- β -glucoside improves obesity and triglyceride metabolism in KK-Ay mice by regulating lipoprotein lipase activity. *J Sci Food Agric* 91:1006–1013.

You Y, Yuan X, Liu X et al (2017) Cyanidin-3-glucoside increases whole body energy metabolism by upregulating brown adipose tissue mitochondrial function. *Mol Nutr Food Res* 61(11).

Confirmation regarding the “re-use” of published paper

The contents previously in Cytotechnology Springer Nature Netherlands, Jan 1, 2018 (<https://doi.org/10.1007/s10616-018-0242-4>) are re-used in this dissertation under the terms of the Creative Commons CC BY license.